VYNE Therapeutics
VYNE
56 hedge funds and large institutions have $68.4M invested in VYNE Therapeutics in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 11 closing their positions.
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
21% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 14
8% more funds holding
Funds holding: 52 → 56 (+4)
0.01% more ownership
Funds ownership: 0.99% → 0.99% (+0.01%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
57% less capital invested
Capital invested by funds: $161M → $68.4M (-$92.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.6M |
| 2 |
First Manhattan
New York
|
+$2.35M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$1.42M |
| 4 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$1.07M |
| 5 |
JP Morgan Chase
New York
|
+$736K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$4.66M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.25M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$2.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.87M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$1.04M |
VYNE Hedge Fund Activity: Q4 2018 in Review
56 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2018, worth a combined $68.4M — down 57% from $161M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VYNE positions and 11 closed out — a net gain of 4 holders — while 17 added to existing stakes and 14 trimmed.
The largest buyer was Great Point Partners, adding an estimated $5.6M. The largest seller was OrbiMed, exiting entirely with an estimated $4.66M sold.
- 56 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2018, up from 52 in Q3 2018.
- Funds reported $68.4M of VYNE Therapeutics stock for Q4 2018, down 57% quarter-over-quarter.
- 15 funds opened new VYNE Therapeutics positions in Q4 2018 and 11 closed out, a net change of +4 holders.
- The largest VYNE Therapeutics buyer in Q4 2018 was Great Point Partners, an estimated $5.6M added.
- The largest VYNE Therapeutics seller in Q4 2018 was OrbiMed, an estimated $4.66M sold.
Based on aggregated 13F filings for Q4 2018.